PDF(Pubmed)
Abstract：
Non-communicable chronic diseases (NCDs) have become a major global health concern. They constitute the leading cause of disabilities, increased morbidity, mortality, and socio-economic disasters worldwide. Medical condition-specific digital biomarker (DB) panels have emerged as valuable tools to manage NCDs. DBs refer to the measurable and quantifiable physiological, behavioral, and environmental parameters collected for an individual through innovative digital health technologies, including wearables, smart devices, and medical sensors. By leveraging digital technologies, healthcare providers can gather real-time data and insights, enabling them to deliver more proactive and tailored interventions to individuals at risk and patients diagnosed with NCDs. Continuous monitoring of relevant health parameters through wearable devices or smartphone applications allows patients and clinicians to track the progression of NCDs in real time. With the introduction of digital biomarker monitoring (DBM), a new quality of primary and secondary healthcare is being offered with promising opportunities for health risk assessment and protection against health-to-disease transitions in vulnerable sub-populations. DBM enables healthcare providers to take the most cost-effective targeted preventive measures, to detect disease developments early, and to introduce personalized interventions. Consequently, they benefit the quality of life (QoL) of affected individuals, healthcare economy, and society at large. DBM is instrumental for the paradigm shift from reactive medical services to 3PM approach promoted by the European Association for Predictive, Preventive, and Personalized Medicine (EPMA) involving 3PM experts from 55 countries worldwide. This position manuscript consolidates multi-professional expertise in the area, demonstrating clinically relevant examples and providing the roadmap for implementing 3PM concepts facilitated through DBs.
摘要：
慢性非传染性疾病（NCDs）已成为全球主要的健康问题。它们是造成残疾的主要原因，发病率增加，死亡率,和世界范围内的社会经济灾难。特定于医疗条件的数字生物标志物（DB）小组已成为管理非传染性疾病的宝贵工具。DB是指可测量和可量化的生理，行为，以及通过创新的数字健康技术为个人收集的环境参数，包括可穿戴设备,智能设备，和医疗传感器。通过利用数字技术，医疗保健提供商可以收集实时数据和见解，使他们能够向有风险的个人和被诊断为非传染性疾病的患者提供更积极和有针对性的干预措施。通过可穿戴设备或智能手机应用程序持续监测相关健康参数，使患者和临床医生能够实时跟踪非传染性疾病的进展。随着数字生物标志物监测(DBM)的引入，新质量的初级和二级医疗保健正在提供有希望的机会进行健康风险评估，并在弱势亚人群中防止健康到疾病的转变。DBM使医疗保健提供者能够采取最具成本效益的针对性预防措施，为了及早发现疾病的发展，并引入个性化干预措施。因此,它们有利于受影响个体的生活质量(QoL)，医疗保健经济，和整个社会。DBM有助于欧洲预测协会推动的从被动医疗服务到3PM方法的范式转变，预防性,以及来自全球55个国家的3PM专家参与的个性化医学（EPMA）。这份职位手稿巩固了该地区的多专业知识，演示临床相关示例，并提供通过数据库促进实施3PM概念的路线图。
